Latest

neuropharmacology

·August 7, 2023·6 min read

Innovative Antibody Counteracts Deadly Opioid Overdoses

Researchers developed an antibody with significant potential to reverse the lethal effects of a carfentanil overdose, according to preclinical tests. Carfentanil, a potent variant of the synthetic opioid fentanyl, is often mixed with illicit drugs, leading to a high number of overdoses.

Featured Neuroscience Psychology

·July 26, 2023·7 min read

Glutamate Receptor Activation: A Potential Cure for Opioid Addiction?

Scientists discovered a potential new weapon in the battle against opioid use disorder (OUD), a condition that affects over two million people in the U.S. alone. The drug, ADX106772, acts on metabotropic glutamate 2 receptors in the brain, leading to a reduction in oxycodone intake and drug-seeking behavior in an animal model.

Featured Neurology Neuroscience Pain

·July 24, 2023·5 min read

Easing Pain, Safely: Antidepressant’s Promise for Neuropathic Pain Relief

Neuropathic pain, impacting an estimated 10% of the global population, could be tackled more safely and effectively with the atypical antidepressant tianeptine. Researchers found that tianeptine offers rapid, long-lasting relief from pain with a lower risk of addiction.

Featured Neurology Neuroscience

·July 20, 2023·3 min read

Is A Fitness Supplement A Potential Ally Against Alzheimer’s?

Researchers have found that the muscle-building supplement HMB (beta-hydroxy beta-methylbutyrate), commonly used by bodybuilders, could help protect memory and slow the progression of Alzheimer's disease. Mouse studies showed HMB reduced Alzheimer's plaques and enhanced factors for neuronal growth, safeguarding learning and memory.

Featured Neurology Neuroscience

·July 17, 2023·5 min read

Donanemab: A Promising Step Forward in Early-Stage Alzheimer’s Treatment

A third new Alzheimer's drug, donanemab, is set for FDA approval, marking a significant step in slowing the progression of the disease. However, these treatments, which work best in the disease's early stages, may not suffice for patients with advanced Alzheimer's.

Featured Neurology Neuroscience

·July 17, 2023·4 min read

Anti-Inflammatory Drugs: A Pathway to Alzheimer’s Treatment

A new study sheds light on how certain anti-inflammatory drugs may prove to be effective treatments for Alzheimer's disease (AD). The team zeroed in on a protein known as p38.

Featured Neurology Neuroscience

·July 1, 2023·6 min read

Lecanemab Alzheimer’s Treatment Set for FDA Approval

Doctors are preparing to administer lecanemab, a promising new Alzheimer's disease treatment nearing FDA approval. This therapy, marketed as Leqembi, slows cognitive decline by extracting amyloid proteins from the brain, thus decreasing tau protein accumulation.

Featured Neuroscience Psychology

·June 16, 2023·6 min read

Psychedelic Breakthroughs: Balancing Promise and Peril in Mental Health Therapies

Psychedelics offer promise as potential treatments for mental health disorders, from depression to PTSD. However, the unique mind-altering effects of these substances also present distinct ethical and clinical challenges.

Featured Neuroscience

·June 13, 2023·5 min read

Unveiling a Cognitive Booster Hidden in a Laxative

A new study has investigated how the laxative prucalopride, known to activate serotonin receptors, affects resting brain activity in healthy adults. The study discovered that those who took prucalopride demonstrated increased functional connectivity between major cognitive networks in their resting-state.

Featured Neurology Neuroscience

·June 13, 2023·5 min read

Antihistamine Sparks Hope for Myelin Repair in Multiple Sclerosis

A new study paves the way for potential treatments for Multiple Sclerosis (MS) by identifying the OTC antihistamine, clemastine, as an effective drug for brain repair. Utilizing a newly-developed MRI scan technique, scientists were able to observe and measure the impact of clemastine on brain myelin levels.

Brain Cancer Featured Neuroscience

·June 4, 2023·6 min read

Targeted Therapy Vorasidenib Offers Hope for Deadly Brain Tumors

A newly developed drug, Vorasidenib, has shown promise in prolonging progression-free survival for patients with a subtype of glioma. The international study found that patients taking Vorasidenib could go nearly 17 more months without their cancer worsening, postponing the need for radiation and chemotherapy.

Brain Cancer Featured Neurology Neuroscience

·June 2, 2023·6 min read

Promising Phase 2 Trial Results for Pembrolizumab in Metastatic Brain Cancer

A phase 2 clinical trial of pembrolizumab has shown promising results, with 42% of patients with metastatic brain cancer benefiting from the treatment. The trial found that pembrolizumab, an immunotherapy, was tolerated and demonstrated clinical benefit in patients with brain metastases.